Chemical pleurodesis and somatostatin in treating spontaneous chylothorax in pediatric patients: a retrospective analysis and review of the literature

Background Chylothorax is a rare disease, defined as an abnormal accumulation of chylous lymphatic effusion in thoracic cavity, with a high mortality rate in pediatric patients. At present, there are few studies on the treatment of pediatric chylothorax, and conservative treatments like somatostatin (SST) and pleurodesis are performed empirically. SST has been used for treating pediatric chylothorax over 20 years, and povidone-iodine chemical pleurodesis (PICP) is adopted in recent years with a high cure rate, but both the effect are still uncertain. The safety and efficacy of SST and PICP in treating pediatric chylothorax was compared in this study. Methods From January 2009 to May 2020, 27 pediatric chylothorax patients who accepted life support, SST and PICP treatment were retrospectively reviewed in this study. Their medical history, clinical manifestations, pleural effusion examinations, treatment methods, effects, and complications were screened. PICP and SST was performed in 19 and 8 children, respectively. Each patient was followed up after discharge from the hospital. Results After admission, chest X-ray and ultrasound diagnosed pleural effusion in 27 patients (18 males and 9 females), including 13 and 6 cases on the left and right side, and 8 cases on both sides. In the pleural effusion, the mean leukocyte count was (9,826±9,482)×106/L, the mean lymphocyte ratio was (84.82±6.58)%, the mean triglyceride content was 7.11±6.63 mmol/L. In PICP and SST group, the mean length of stay was 38.42±19.42 and 35.13±12.72 d (P=0.664), the mean time of thoracic drainage was 24.58±16.34 and 19.63±8.88 d (P=0.440), the mean time of parenteral nutrition was 27.16±18.29 and 25.25±13.52 d (P=0.793), respectively. PICP was performed for 3.16±2.27 times, and SST was used for 14.75±9.08 d with the dosage of 0.5 to 10 µg/kg/hour. After the treatment, all patients in PICP group had mild chest pain and low-grade fever, and 12 cases were observed with transient decrease of oxygen saturation. Eight patients in SST group had nausea and vomit, and 1 child had diarrhea simultaneously. Both were cured by symptomatic treatment, thoracic drainage and discontinuing using SST. Three children were diagnosed with refractory chylothorax and cured by PICP after SST. Pleural effusion in 27 patients was finally absorbed. All of them achieved a clinical cure successfully, and there was no recurrence during discharge follow-up. Conclusions PICP has a high success rate and few adverse reactions in treating spontaneous chylothorax in pediatric patients, expected to be a new treatment option for pediatric chylothorax after SST.

[1]  Wei-Guang Long,et al.  Povidone-iodine chemical pleurodesis in treating spontaneous chylothorax in pediatric patients. , 2020, Annals of palliative medicine.

[2]  A. Concheiro-Guisán,et al.  A Review of the Practicality of Feeding Defatted Human Milk in the Treatment of Congenital Chylothorax. , 2019, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.

[3]  R. Krenke,et al.  Chemical pleurodesis – a review of mechanisms involved in pleural space obliteration , 2019, Respiratory Research.

[4]  I. Matus,et al.  Ambulatory Iodopovidone Instillation Via Indwelling Pleural Catheters For Malignant Pleural Effusions , 2019, Journal of bronchology & interventional pulmonology.

[5]  Xi Zheng,et al.  A modified pleurodesis in treating postoperative chylothorax. , 2019, Annals of translational medicine.

[6]  F. Pons,et al.  An uncommon therapeutic option for a challenging cause of pleural effusion , 2019, Breathe.

[7]  Kamran Dehghan Idiopathic Chylothorax in a Term Neonate and Successful Treatment with Octreotide and Medium Chain Triglyceride -Enriched Formula: A Case Report , 2019 .

[8]  D. Azar,et al.  Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies—A review , 2018, Medicinal research reviews.

[9]  L. Ramenghi,et al.  Octreotide for congenital and acquired chylothorax in newborns: A systematic review , 2018, Journal of paediatrics and child health.

[10]  L. Claesson‐Welsh,et al.  Cytokines regulating lymphangiogenesis. , 2018, Current opinion in immunology.

[11]  A. Malhotra,et al.  Octreotide Use in Neonates: A Case Series , 2018, Drugs in R&D.

[12]  R. Basiri,et al.  The effect of iodopovidone versus bleomycin in chemical pleurodesis , 2018, Asian cardiovascular & thoracic annals.

[13]  Melissa M Deer,et al.  Successful management of extremely high‐output refractory congenital chylothorax with chemical pleurodesis using 4% povidone–iodine and propranolol: a case report , 2018, Clinical case reports.

[14]  U. Boston,et al.  Diaphragmatic fenestration for refractory chylothorax after congenital cardiac surgery in infants , 2017, The Journal of thoracic and cardiovascular surgery.

[15]  Niki Matusko,et al.  Evidence-based management of chylothorax in infants. , 2017, Journal of pediatric surgery.

[16]  C. Pessotti,et al.  Incidence and Treatment of Chylothorax in Children Undergoing Corrective Surgery for Congenital Heart Diseases , 2017, Brazilian journal of cardiovascular surgery.

[17]  M. Azam,et al.  Bilateral spontaneous chylothorax in a newborn and response to octreotide therapy , 2017 .

[18]  A. Bouziri,et al.  Povidone Iodine Pleurodesis for Refractory Congenital Chylothorax: A Review of Literature. , 2016, La Tunisie medicale.

[19]  Yayoi Miyazono,et al.  High Dose Octreotide for the Treatment of Chylothorax in Three Neonates , 2016 .

[20]  P. Tsao,et al.  Prenatal Therapy Improves the Survival of Premature Infants with Congenital Chylothorax. , 2016, Pediatrics and neonatology.

[21]  A. Conforti,et al.  Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review. , 2015, Journal of pediatric surgery.

[22]  U. Çakır,et al.  Report of a case of neonatal chylothorax that responded to long-term octreotide treatment, and review of the literature. , 2015, The Turkish journal of pediatrics.

[23]  J. D. Tutor Chylothorax in Infants and Children , 2014, Pediatrics.

[24]  S. Matsuo,et al.  Management of Refractory Chylothorax After Pediatric Cardiovascular Surgery , 2013, Pediatric Cardiology.

[25]  P. Shah,et al.  Octreotide for the treatment of chylothorax in neonates. , 2010, The Cochrane database of systematic reviews.

[26]  S. Murki,et al.  Congenital Chylothorax - Successful management with chemical pleurodesis , 2010, Indian journal of pediatrics.

[27]  M. D. Laet,et al.  Thoracoscopic thoracic duct sealing with LigaSure in two children with refractory postoperative chylothorax. , 2007, Journal of laparoendoscopic & advanced surgical techniques. Part A.

[28]  K. Lakhoo,et al.  Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review , 2006, Intensive Care Medicine.

[29]  O. Brissaud,et al.  Congenital idiopathic chylothorax in neonates: chemical pleurodesis with povidone-iodine (Betadine) , 2003, Archives of disease in childhood. Fetal and neonatal edition.

[30]  R. Chamberlain,et al.  The changing management of chylothorax in the modern era. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[31]  F. Hmami,et al.  [Congenital chylothorax: rapid and complete response to polyvidone iodine]. , 2014, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.